XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination (Tables)
9 Months Ended
Sep. 30, 2021
Business Acquisition [Line Items]  
Reconciles the Elements of Business Combination to Consolidated Statements
The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity for the nine months ended September 30, 2021:

   
Recapitalization
 
Cash- AMCI’s trust and cash (net of redemptions)
 
$
93,310,599
 
Cash – PIPE plus interest
   
65,000,118
 
Less transaction costs and advisory fees paid
   
(17,188,519
)
Less non-cash warrant liability assumed
    (33,116,321 )
Net Business Combination and PIPE financing
 
$
108,005,877
 
Common Stock Issued Following the Consummation of Business Combination
The number of shares of common stock issued immediately following the consummation of the Business Combination:

   
Recapitalization
 
Class A Common A stock of AMCI, outstanding prior to Business Combination
   
9,061,136
 
Less Redemption of AMCI shares
   
(1,606
)
Class B Common Stock of AMCI, outstanding prior to Business Combination
   
5,513,019
 
Shares issued in PIPE
   
6,500,000
 
Business Combination and PIPE financing shares
   
21,072,549
 
Legacy Advent Shares
   
25,033,398
 
Total shares of Common Stock immediately after Business Combination
   
46,105,947
 
UltraCell LLC [Member]  
Business Acquisition [Line Items]  
Assets Acquired and Liabilities Assumed
The assets acquired and liabilities assumed at the date of acquisition were as follows:

Current assets
     
Cash and cash equivalents
 
$
77,129
 
Other current assets
   
658,332
 
Total current assets
 
$
735,461
 
Non-current assets
   
9,187
 
Total assets
 
$
744,649
 
         
Current liabilities
   
110,179
 
Non-current liabilities
   
-
 
Total liabilities
 
$
110,179
 
         
Net assets acquired
 
$
634,469
 

Goodwill arising on acquisition

Cost of investment
 
$
6,000,000
 
Net assets value
   
634,469
 
Consideration to be allocated
 
$
5,365,531
 
Fair value adjustment - New intangibles
       
     Trade name "UltraCell"
   
405,931
 
     Patented technology
   
4,328,228
 
Total intangibles acquired
 
$
4,734,159
 
Remaining Goodwill
 
$
631,372
 
SerEnergy and FES [Member]  
Business Acquisition [Line Items]  
Assets Acquired and Liabilities Assumed
The assets acquired and liabilities assumed at the date of acquisition were as follows:

Current assets
     
Cash and cash equivalents
 
$
4,366,802
 
Other current assets
   
10,454,864
 
Total current assets
 
$
14,821,665
 
Non-current assets
   
5,434,180
 
Total assets
 
$
20,255,845
 
         
Current liabilities
   
5,818,170
 
Non-current liabilities
   
1,179,618
 
Total liabilities
 
$
6,997,788
 
         
Net assets acquired
 
$
13,258,057
 

Goodwill arising on acquisition

Cost of investment
     
Cash consideration
 
$
22,236,111
 
Share consideration
   
37,923,860
 
Total cost of investment
   
60,159,971
 
Less: Net assets value
   
13,258,057
 
Original excess purchase price
 
$
46,901,914
 
Fair value adjustments
       
     Real Property
   
76,000
 
New intangibles:
       
     Patents
   
17,275,000
 
     Process know-how (IPR&D)
   
2,599,000
 
     Order backlog
   
247,000
 
Total intangibles acquired
 
$
20,121,000
 
Deferred tax liability arising from the recognition of intangibles and real property valuation
   
(4,444,000
)
Deferred tax assets on tax losses carried forward
   
1,915,000
 
Remaining Goodwill
 
$
29,233,914